



Clinical trial results:

A Phase II, Open label, Non randomised, Non comparative, Multicentre study to assess the efficacy and safety of olaparib given orally twice daily in patients with advanced cancers who have a confirmed genetic BRCA 1 and/or BRCA2 mutation

Summary

EudraCT number	2010-022278-15
Trial protocol	DE SE ES
Global end of trial date	12 August 2024

Results information

Result version number	v1 (current)
This version publication date	28 August 2025
First version publication date	28 August 2025

Trial information

Trial identification

Sponsor protocol code	D0810C00042
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01078662
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	151 85, Sodertalje, Sweden,
Public contact	Global Clinical Lead, AstraZeneca, +1 8772409479, information.center@astrazeneca.com
Scientific contact	Global Clinical Lead, AstraZeneca, +1 8772409479, information.center@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 July 2012
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 July 2012
Global end of trial reached?	Yes
Global end of trial date	12 August 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study was to assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response

Protection of trial subjects:

The conduct of this clinical study met all local and regulatory requirements. This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Conference on Harmonization/Good Clinical Practice (GCP), applicable regulatory requirements, and the AstraZeneca policy on Bioethics.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 February 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 39
Country: Number of subjects enrolled	Germany: 36
Country: Number of subjects enrolled	Spain: 18
Country: Number of subjects enrolled	Israel: 136
Country: Number of subjects enrolled	Sweden: 6
Country: Number of subjects enrolled	United States: 63
Worldwide total number of subjects	298
EEA total number of subjects	60

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	250
From 65 to 84 years	48
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was conducted at 13 sites across Israel, Germany, Spain, Australia, USA, Sweden. Enrolment started in Feb 2010 and was completed in Jul 2012. In total, 298 patients had received treatment (olaparib).

Pre-assignment

Screening details:

Patients >17 years age with histologically and/or cytologically confirmed malignant solid tumours, refractory to standard therapy for which no suitable effective/curative therapy. Patients with confirmed deleterious or suspected deleterious BRCA mutation, Eastern Co-operative Oncology Group performance status ≤ 2 and life expectancy of ≥ 12 weeks.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Breast Cancer

Arm description:

Patients with primary cancer site = breast. Receiving olaparib 400mg BID

Arm type	Experimental
Investigational medicinal product name	Olaparib
Investigational medicinal product code	AZD2281
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Olaparib was dispensed to patients on Day 1 and every 28 days thereafter until the patient completed the study, patient was withdrawn from the study, or the study was closed. Patients were to take Olaparib 400 mg (50 mg \times 8 capsules) bd orally at the same time each day, approximately 12 hours apart, morning and evening, with a glass of water. Patients were instructed to take their doses of Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption. The Olaparib capsules were to be swallowed whole. The capsules were not to be chewed, crushed, dissolved, or divided. Patients were instructed to take their doses of Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption.

Arm title	Ovarian Cancer
------------------	----------------

Arm description:

Patients with primary cancer site = ovary. Receiving olaparib 400mg BID

Arm type	Experimental
Investigational medicinal product name	Olaparib
Investigational medicinal product code	AZD2281
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Olaparib was dispensed to patients on Day 1 and every 28 days thereafter until the patient completed the study, patient was withdrawn from the study, or the study was closed. Patients were to take Olaparib 400 mg (50 mg \times 8 capsules) bd orally at the same time each day, approximately 12 hours apart, morning and evening, with a glass of water. Patients were instructed to take their doses of

Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption. The Olaparib capsules were to be swallowed whole. The capsules were not to be chewed, crushed, dissolved, or divided. Patients were instructed to take their doses of Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption.

Arm title	Pancreatic Cancer
Arm description:	
Patients with primary cancer site = pancreas. Receiving olaparib 400mg BID	
Arm type	Experimental
Investigational medicinal product name	Olaparib
Investigational medicinal product code	AZD2281
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Olaparib was dispensed to patients on Day 1 and every 28 days thereafter until the patient completed the study, patient was withdrawn from the study, or the study was closed. Patients were to take Olaparib 400 mg (50 mg ×8 capsules) bd orally at the same time each day, approximately 12 hours apart, morning and evening, with a glass of water. Patients were instructed to take their doses of Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption. The Olaparib capsules were to be swallowed whole. The capsules were not to be chewed, crushed, dissolved, or divided. Patients were instructed to take their doses of Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption.

Arm title	Prostate Cancer
Arm description:	
Patients with primary cancer site = prostate. Receiving olaparib 400mg BID	
Arm type	Experimental
Investigational medicinal product name	Olaparib
Investigational medicinal product code	AZD2281
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Olaparib was dispensed to patients on Day 1 and every 28 days thereafter until the patient completed the study, patient was withdrawn from the study, or the study was closed. Patients were to take Olaparib 400 mg (50 mg ×8 capsules) bd orally at the same time each day, approximately 12 hours apart, morning and evening, with a glass of water. Patients were instructed to take their doses of Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption. The Olaparib capsules were to be swallowed whole. The capsules were not to be chewed, crushed, dissolved, or divided. Patients were instructed to take their doses of Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption.

Arm title	Other Cancers
Arm description:	
Patients with other primary cancers. Receiving olaparib 400mg BID	
Arm type	Experimental
Investigational medicinal product name	Olaparib
Investigational medicinal product code	AZD2281
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Olaparib was dispensed to patients on Day 1 and every 28 days thereafter until the patient completed the study, patient was withdrawn from the study, or the study was closed. Patients were to take

Olaparib 400 mg (50 mg ×8 capsules) bd orally at the same time each day, approximately 12 hours apart, morning and evening, with a glass of water. Patients were instructed to take their doses of Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption. The Olaparib capsules were to be swallowed whole. The capsules were not to be chewed, crushed, dissolved, or divided. Patients were instructed to take their doses of Olaparib at least 1 hour after food and had to refrain from eating for next 2 hours due to potential effect of food on absorption.

Number of subjects in period 1	Breast Cancer	Ovarian Cancer	Pancreatic Cancer
Started	62	193	23
Completed	4	25	2
Not completed	58	168	21
Consent withdrawn by subject	4	11	1
Patients reached data cut-off	12	53	2
Death (patients in survival followup included)	41	103	18
Lost to follow-up	1	-	-
Protocol deviation	-	1	-

Number of subjects in period 1	Prostate Cancer	Other Cancers
Started	8	12
Completed	1	1
Not completed	7	11
Consent withdrawn by subject	-	-
Patients reached data cut-off	2	3
Death (patients in survival followup included)	5	8
Lost to follow-up	-	-
Protocol deviation	-	-

Baseline characteristics

Reporting groups

Reporting group title	Breast Cancer
Reporting group description:	
Patients with primary cancer site = breast. Receiving olaparib 400mg BID	
Reporting group title	Ovarian Cancer
Reporting group description:	
Patients with primary cancer site = ovary. Receiving olaparib 400mg BID	
Reporting group title	Pancreatic Cancer
Reporting group description:	
Patients with primary cancer site = pancreas. Receiving olaparib 400mg BID	
Reporting group title	Prostate Cancer
Reporting group description:	
Patients with primary cancer site = prostate. Receiving olaparib 400mg BID	
Reporting group title	Other Cancers
Reporting group description:	
Patients with other primary cancers. Receiving olaparib 400mg BID	

Reporting group values	Breast Cancer	Ovarian Cancer	Pancreatic Cancer
Number of subjects	62	193	23
Age Categorical			
Age by category			
Units:			
< 50 years	33	40	6
>=50 to <65 years	28	117	14
>= 65 years	1	36	3
Age Continuous			
Age at time of screening			
Units: years			
arithmetic mean	47.6	57.2	57.1
standard deviation	± 9.69	± 9.28	± 7.99
Sex: Female, Male			
Gender			
Units:			
Female	61	193	10
Male	1	0	13
Race/Ethnicity, Customized			
Race			
Units: Subjects			
White	60	183	21
Black or African American	0	1	1
Asian	1	8	1
Other	1	1	0

Reporting group values	Prostate Cancer	Other Cancers	Total
Number of subjects	8	12	298

Age Categorical			
Age by category			
Units:			
< 50 years	0	4	83
>=50 to <65 years	3	5	167
>= 65 years	5	3	48
Age Continuous			
Age at time of screening			
Units: years			
arithmetic mean	66.6	54.9	
standard deviation	± 9.86	± 12.38	-
Sex: Female, Male			
Gender			
Units:			
Female	0	8	272
Male	8	4	26
Race/Ethnicity, Customized			
Race			
Units: Subjects			
White	8	11	283
Black or African American	0	0	2
Asian	0	1	11
Other	0	0	2

End points

End points reporting groups

Reporting group title	Breast Cancer
Reporting group description:	
Patients with primary cancer site = breast. Receiving olaparib 400mg BID	
Reporting group title	Ovarian Cancer
Reporting group description:	
Patients with primary cancer site = ovary. Receiving olaparib 400mg BID	
Reporting group title	Pancreatic Cancer
Reporting group description:	
Patients with primary cancer site = pancreas. Receiving olaparib 400mg BID	
Reporting group title	Prostate Cancer
Reporting group description:	
Patients with primary cancer site = prostate. Receiving olaparib 400mg BID	
Reporting group title	Other Cancers
Reporting group description:	
Patients with other primary cancers. Receiving olaparib 400mg BID	

Primary: Tumour response rate

End point title	Tumour response rate ^[1]
End point description:	
Tumour response rate is the proportion of patients who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1). Full analysis set - all treated patients.	
End point type	Primary
End point timeframe:	
Tumour assessments carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Summary of analysis of tumour response rate has been included here

End point values	Breast Cancer	Ovarian Cancer	Pancreatic Cancer	Prostate Cancer
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	193	23	8
Units: Percentage of participants				
number (confidence interval 95%)	12.9 (5.74 to 23.85)	31.1 (24.64 to 38.13)	21.7 (7.46 to 43.7)	50 (15.7 to 84.3)

End point values	Other Cancers			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Percentage of participants				
number (confidence interval 95%)	8.3 (0.21 to			

Statistical analyses

No statistical analyses for this end point

Secondary: Objective response rate

End point title	Objective response rate
-----------------	-------------------------

End point description:

Objective response rate is the proportion of patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1). Measurable disease analysis set - all treated patients having at least one measurable lesion at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumour assessments carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months

End point values	Breast Cancer	Ovarian Cancer	Pancreatic Cancer	Prostate Cancer
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	58	167	23	7
Units: Percentage of participants				
number (confidence interval 95%)	13.8 (6.15 to 25.38)	35.9 (28.66 to 43.7)	21.7 (7.46 to 43.7)	57.1 (18.41 to 90.1)

End point values	Other Cancers			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Percentage of participants				
number (confidence interval 95%)	9.1 (0.23 to 41.28)			

Statistical analyses

No statistical analyses for this end point

Secondary: Progression free survival

End point title	Progression free survival ^[2]
-----------------	--

End point description:

Progression free survival is defined as the duration from first dose till objective progression or death. In absence of progression or death, the time is calculated from first dose till last evaluable scanning visit. Full analysis set - all treated patients. The "Other" cancer group was not analysed in accordance with the protocol.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumour assessments are carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the CSR table results, there are 4 arms summarised for median PFS which are all included here

End point values	Breast Cancer	Ovarian Cancer	Pancreatic Cancer	Prostate Cancer
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	193	23	8
Units: months				
median (inter-quartile range (Q1-Q3))	3.68 (1.76 to 7.52)	7.03 (3.65 to 11.24)	4.55 (1.81 to 8.21)	7.15 (2.63 to 17.45)

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival

End point title	Overall survival ^[3]
-----------------	---------------------------------

End point description:

Overall survival is defined as the duration from first dose till death. In absence of death, the time is calculated from first dose till the date subject last known to be alive. Full analysis set - all treated patients. The "Other" cancer group was not analysed in accordance with the protocol.

End point type	Secondary
----------------	-----------

End point timeframe:

Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed maximum up to 29 months

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the CSR table results, there are 4 arms summarised for median OS which are all included here

End point values	Breast Cancer	Ovarian Cancer	Pancreatic Cancer	Prostate Cancer
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	193	23	8
Units: months				
median (inter-quartile range (Q1-Q3))	11.01 (5.68 to 24.18)	16.62 (9.43 to 99999)	9.81 (3.84 to 16.62)	18.38 (6.24 to 25.46)

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival rate at 12 months

End point title	Overall survival rate at 12 months ^[4]
-----------------	---

End point description:

Overall survival rate at 12 months is defined as the proportion of patients who are alive 12 months after date of first dose. Full analysis set - all treated patients. The "Other" cancer group was not analysed in accordance with the protocol.

End point type	Secondary
----------------	-----------

End point timeframe:

Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed maximum up to 29 months

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the CSR table results, there are 4 arms summarised for OS survival rate at 12 months which are all included here

End point values	Breast Cancer	Ovarian Cancer	Pancreatic Cancer	Prostate Cancer
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	193	23	8
Units: Percentage of participants				
number (not applicable)	44.7	64.4	40.9	50

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of response

End point title	Duration of response
-----------------	----------------------

End point description:

Duration of response is calculated from the date of first documented response (complete or partial) until date of documented progression (as defined by RECIST 1.1) or death (by any cause) in the absence of disease progression. Full analysis set - all treated patients who had at least one complete or partial response during the assessment period.

End point type	Secondary
----------------	-----------

End point timeframe:

From onset of first occurrence of complete or partial response till documented progression or death by any cause in the absence of progression, assessed maximum up to 29 months

End point values	Breast Cancer	Ovarian Cancer	Pancreatic Cancer	Prostate Cancer
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	60	5	4
Units: days				
median (inter-quartile range (Q1-Q3))	204 (149.5 to 405)	225 (143 to 410)	134 (131 to 141)	326.5 (164 to 476)

End point values	Other Cancers			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: days				
median (inter-quartile range (Q1-Q3))	165 (165 to 165)			

Statistical analyses

No statistical analyses for this end point

Secondary: Disease control rate at week 16

End point title	Disease control rate at week 16
End point description:	
Disease control rate is the proportion of patients with best response of complete or partial response or stable disease according to definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) till week 16. Full analysis set - all treated patients.	
End point type	Secondary
End point timeframe:	
Tumour assessments carried out at baseline ie 28 days before first study drug dose and then at week 8 and week 16	

End point values	Breast Cancer	Ovarian Cancer	Pancreatic Cancer	Prostate Cancer
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	193	23	8
Units: Percentage of participants				
number (confidence interval 95%)	37.1 (25.16 to 50.31)	58 (50.73 to 65.08)	47.8 (26.82 to 69.41)	62.5 (24.49 to 91.48)

End point values	Other Cancers			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Percentage of participants				
number (confidence interval 95%)	33.3 (9.92 to 65.11)			

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

If any SAE occurs in the course of the study, then within one day ie, immediately but no later than the end of the next business day of when he or she becomes aware of it.

Adverse event reporting additional description:

The designated AstraZeneca representative works with the investigator to ensure that all the necessary information is provided to the AstraZeneca Patient Safety data entry site within one calendar day of initial receipt for fatal and life threatening events and within five calendar days of initial receipt for all other SAEs.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	15

Reporting groups

Reporting group title	OLAPARIB
-----------------------	----------

Reporting group description: -

Serious adverse events	OLAPARIB		
Total subjects affected by serious adverse events			
subjects affected / exposed	90 / 298 (30.20%)		
number of deaths (all causes)	175		
number of deaths resulting from adverse events	8		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
GASTRIC CANCER			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ACUTE MYELOID LEUKAEMIA			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
ACUTE LEUKAEMIA			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
General disorders and administration site conditions			

DEVICE OCCLUSION			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
FATIGUE			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
PYREXIA			
subjects affected / exposed	3 / 298 (1.01%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
VAGINAL HAEMORRHAGE			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
PULMONARY EMBOLISM			

subjects affected / exposed	4 / 298 (1.34%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 1		
PLEURAL EFFUSION			
subjects affected / exposed	4 / 298 (1.34%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
DYSPNOEA			
subjects affected / exposed	4 / 298 (1.34%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
SUICIDE ATTEMPT			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ANXIETY			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
HAEMOGLOBIN DECREASED			
subjects affected / exposed	2 / 298 (0.67%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
NEUTROPHIL COUNT DECREASED			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

PLATELET COUNT DECREASED			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
WOUND DEHISCENCE			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
TOXICITY TO VARIOUS AGENTS			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
HIP FRACTURE			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
PERICARDIAL EFFUSION			
subjects affected / exposed	2 / 298 (0.67%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
CEREBROVASCULAR ACCIDENT			
subjects affected / exposed	2 / 298 (0.67%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 1		
CEREBRAL ISCHAEMIA			

subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SYNCOPE			
subjects affected / exposed	2 / 298 (0.67%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	13 / 298 (4.36%)		
occurrences causally related to treatment / all	12 / 14		
deaths causally related to treatment / all	0 / 0		
THROMBOCYTOPENIA			
subjects affected / exposed	3 / 298 (1.01%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
LEUKOPENIA			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
FEBRILE NEUTROPENIA			
subjects affected / exposed	2 / 298 (0.67%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
NEUTROPENIA			
subjects affected / exposed	3 / 298 (1.01%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
VERTIGO			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			

RETINAL DETACHMENT			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
DIPLOPIA			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
OBSTRUCTION GASTRIC			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
LARGE INTESTINAL OBSTRUCTION			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
INTESTINAL MASS			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ENTERITIS			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
INTESTINAL OBSTRUCTION			
subjects affected / exposed	7 / 298 (2.35%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 0		
ABDOMINAL HERNIA			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ABDOMINAL PAIN			

subjects affected / exposed	11 / 298 (3.69%)		
occurrences causally related to treatment / all	0 / 12		
deaths causally related to treatment / all	0 / 0		
ASCITES			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CONSTIPATION			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
DYSPHAGIA			
subjects affected / exposed	3 / 298 (1.01%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
GASTROINTESTINAL OBSTRUCTION			
subjects affected / exposed	2 / 298 (0.67%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
GASTROINTESTINAL PERFORATION			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
NAUSEA			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
VOMITING			
subjects affected / exposed	5 / 298 (1.68%)		
occurrences causally related to treatment / all	3 / 6		
deaths causally related to treatment / all	0 / 0		
SMALL INTESTINAL OBSTRUCTION			

subjects affected / exposed	7 / 298 (2.35%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
RECTAL HAEMORRHAGE			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
PANCREATITIS			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
OESOPHAGEAL STENOSIS			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ILEUS			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
CHOLANGITIS			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
URINARY RETENTION			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
RENAL FAILURE ACUTE			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue			

disorders				
OSTEONECROSIS OF JAW				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
MUSCULAR WEAKNESS				
subjects affected / exposed	2 / 298 (0.67%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
HAEMARTHROSIS				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
GROIN PAIN				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
GASTROENTERITIS				
subjects affected / exposed	2 / 298 (0.67%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
DEVICE RELATED SEPSIS				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
URINARY TRACT INFECTION				
subjects affected / exposed	2 / 298 (0.67%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
STAPHYLOCOCCAL SEPSIS				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

ABDOMINAL ABSCESS				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
BACTERAEemia				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
DEVICE RELATED INFECTION				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
ENTEROBACTER SEPSIS				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
INFECTION				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
PNEUMONIA				
subjects affected / exposed	4 / 298 (1.34%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
POSTOPERATIVE WOUND INFECTION				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
SEPSIS				
subjects affected / exposed	1 / 298 (0.34%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
UPPER RESPIRATORY TRACT INFECTION				

subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
UPPER RESPIRATORY TRACT INFECTION BACTERIAL			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
HYPONATRAEMIA			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
HYPOKALAEMIA			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
HYPERKALAEMIA			
subjects affected / exposed	1 / 298 (0.34%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	OLAPARIB		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	290 / 298 (97.32%)		
Investigations			
BLOOD CREATININE INCREASED			
subjects affected / exposed	21 / 298 (7.05%)		
occurrences (all)	21		
WEIGHT DECREASED			
subjects affected / exposed	26 / 298 (8.72%)		
occurrences (all)	26		
Vascular disorders			

HOT FLUSH subjects affected / exposed occurrences (all)	19 / 298 (6.38%) 20		
Nervous system disorders HEADACHE subjects affected / exposed occurrences (all)	48 / 298 (16.11%) 60		
DYSGEUSIA subjects affected / exposed occurrences (all)	47 / 298 (15.77%) 47		
DIZZINESS subjects affected / exposed occurrences (all)	34 / 298 (11.41%) 34		
General disorders and administration site conditions ASTHENIA subjects affected / exposed occurrences (all)	25 / 298 (8.39%) 33		
PYREXIA subjects affected / exposed occurrences (all)	37 / 298 (12.42%) 51		
OEDEMA PERIPHERAL subjects affected / exposed occurrences (all)	41 / 298 (13.76%) 48		
FATIGUE subjects affected / exposed occurrences (all)	176 / 298 (59.06%) 199		
Blood and lymphatic system disorders THROMBOCYTOPENIA subjects affected / exposed occurrences (all)	28 / 298 (9.40%) 36		
LEUKOPENIA subjects affected / exposed occurrences (all)	23 / 298 (7.72%) 35		
ANAEMIA subjects affected / exposed occurrences (all)	90 / 298 (30.20%) 120		

Gastrointestinal disorders			
DYSPEPSIA			
subjects affected / exposed	52 / 298 (17.45%)		
occurrences (all)	54		
DRY MOUTH			
subjects affected / exposed	19 / 298 (6.38%)		
occurrences (all)	20		
DIARRHOEA			
subjects affected / exposed	81 / 298 (27.18%)		
occurrences (all)	103		
ABDOMINAL DISTENSION			
subjects affected / exposed	33 / 298 (11.07%)		
occurrences (all)	35		
ABDOMINAL PAIN			
subjects affected / exposed	66 / 298 (22.15%)		
occurrences (all)	85		
ABDOMINAL PAIN UPPER			
subjects affected / exposed	25 / 298 (8.39%)		
occurrences (all)	27		
CONSTIPATION			
subjects affected / exposed	42 / 298 (14.09%)		
occurrences (all)	53		
VOMITING			
subjects affected / exposed	109 / 298 (36.58%)		
occurrences (all)	158		
NAUSEA			
subjects affected / exposed	176 / 298 (59.06%)		
occurrences (all)	218		
FLATULENCE			
subjects affected / exposed	23 / 298 (7.72%)		
occurrences (all)	28		
Respiratory, thoracic and mediastinal disorders			
OROPHARYNGEAL PAIN			
subjects affected / exposed	16 / 298 (5.37%)		
occurrences (all)	18		
DYSPNOEA EXERTIONAL			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>DYSпноEA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>COUGH</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>15 / 298 (5.03%)</p> <p>15</p> <p>36 / 298 (12.08%)</p> <p>44</p> <p>42 / 298 (14.09%)</p> <p>52</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>RASH</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>15 / 298 (5.03%)</p> <p>16</p>		
<p>Psychiatric disorders</p> <p>ANXIETY</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>INSOMNIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>DEPRESSION</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>17 / 298 (5.70%)</p> <p>17</p> <p>22 / 298 (7.38%)</p> <p>22</p> <p>19 / 298 (6.38%)</p> <p>19</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>MUSCULOSKELETAL PAIN</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>PAIN IN EXTREMITY</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>MUSCULOSKELETAL CHEST PAIN</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ARTHRALGIA</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>BACK PAIN</p>	<p>17 / 298 (5.70%)</p> <p>18</p> <p>25 / 298 (8.39%)</p> <p>26</p> <p>15 / 298 (5.03%)</p> <p>16</p> <p>27 / 298 (9.06%)</p> <p>33</p>		

subjects affected / exposed occurrences (all)	37 / 298 (12.42%) 43		
MUSCLE SPASMS subjects affected / exposed occurrences (all)	27 / 298 (9.06%) 31		
Infections and infestations NASOPHARYNGITIS subjects affected / exposed occurrences (all)	23 / 298 (7.72%) 26		
UPPER RESPIRATORY TRACT INFECTION subjects affected / exposed occurrences (all)	23 / 298 (7.72%) 29		
URINARY TRACT INFECTION subjects affected / exposed occurrences (all)	30 / 298 (10.07%) 44		
Metabolism and nutrition disorders DECREASED APPETITE subjects affected / exposed occurrences (all)	62 / 298 (20.81%) 67		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
31 March 2010	Section 4.1 Inclusion Criteria; criteria 3-8 changed. Section 4.2 Exclusion Criteria, criterion 3 changed. Section 5.6.2 Antiemetics/Antidiarrhoeals revised. Section 5.7 Treatment compliance, 2nd paragraph changed. Section 9.5 Study timetable and end of the study, 1st paragraph changed.
26 August 2010	Protocol Synopsis - Study centre(s) and number of patients planned changed. Protocol Synopsis - Objectives, exploratory objectives added. Protocol Synopsis - Study design, paragraph 2 changed. Protocol Synopsis -Target population revised. Protocol Synopsis - Outcome variable(s), Exploratory outcome variable added. Protocol Synopsis - Statistical Methods, paragraph 1 changed. Section of protocol 2.4 Exploratory objectives added. Section of protocol 3.1 Overall study design and flow chart, paragraph 3, Table 1 and Table 2 are changed. Section of protocol 4.1 Inclusion Criteria; criteria 4, 5, 7 and 8 changed. Section of protocol 4.2 Exclusion criteria added. Section of protocol 5.5.2 Doses and treatment regimens, first paragraph changed. Section of protocol 6.2.2.2 BRCA status - 2nd paragraph added. Section of protocol 6.2.3.4 CT or MRI scans (RECIST 1.1) - 3rd paragraph added. Section of protocol 7.1 Volume of blood revised. Section of protocol 7.2 Handling, storage and destruction of biological samples revised. Section of protocol 7.3 Labelling and shipment of biohazard samples revised. Section of protocol 7.4 Chain of custody of biological samples revised. Section of protocol 7.5 Withdrawal of informed consent for donated biological samples revised. Section of protocol 11.1.2 Secondary Endpoints - only part "Progression free survival (PFS)" changed. Section of protocol 12.3 Determination of sample size revised. Section of protocol 13.2 Overdose - 6th paragraph added.
08 August 2011	Protocol synopsis Study period, Study design, and Duration of treatment revised. Section of protocol 1.1.10 Clinical experience revised. Section of protocol 3.1 Overall study design and flow chart revised. Section of protocol 5.5.6 Management of toxicity of olaparib (monotherapy treatment) revised. Section of protocol 5.8 Discontinuation of investigational product revised. Section of protocol 5.8.1 Procedures for discontinuation of a patient from investigational product revised. Section of protocol 6.2.2 On-trial assessments revised. Section of protocol 6.2.2.2 BRCA status revised. New section in protocol is added: 6.2.2.3 Hormonal receptor status. Section of protocol 6.4.3 Recording of adverse events paragraph Adverse Events based on examinations and tests is changed. Section of protocol 6.4.5 Laboratory safety assessment revised. Section of protocol 6.4.8.1 Pulse and blood pressure revised. New protocol section added: 6.4.9.2 Bone marrow analysis or blood sample cytogenetics. Section of protocol 9.5 Study timetable and end of study revised. Section of protocol 12.2.2.5 Disease Control Rate (DCR) revised. Section of protocol 13.1 Medical emergencies and AstraZeneca contacts revised.

09 July 2021	<p>Addition of language regarding transition from capsule form to tablet form for those patients in continued access phase, including labelling, follow up, overdose and recommended capsule doses to equivalent tablet doses due to discontinuation of capsule manufacture in the following sections: Synopsis, Sections 3.1 Overall study design and flow chart, 5.5.1 Identity of investigational product, 5.5.2 Doses and treatment, 5.5.4 Labelling, 9.5 Study timetable and end of study, 13.2 Overdose and NEW Sections 5.5.7 Dose modifications during the continued access phase and 6.2.3.5 Patients in the continued access phase. Updated language on contraception and length of time on contraception in accordance with update of Investigator's Brochure in Section 5.1 Restrictions during the study, 13.3.1 Maternal exposure and Appendix D Acceptable birth control methods. Updated language on live/bacterial vaccines not being permitted while taking olaparib in accordance with standard olaparib text regarding vaccines in Sections 5.1 Restrictions during the study and 5.6.5 Medications that may NOT be administered. Updated safety language regarding adverse events of special interest in accordance with update of Investigator's Brochure in Section 6.4.3 Recording of adverse events. Removal of contact names and details in title page and Section 13.1 Medical emergencies and AstraZeneca contacts due to contact details out of date and language no longer consistent with current protocol template.</p>
--------------	---

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported